In 2016, Alliance Pharma conducted a Customer Survey to measure satisfaction of our bioanalytical, biopharmaceutical, and drug metabolism services to our clients. Our goal was to assess how we were performing in relation to our business philosophy. Since we measure our success based on the success of our clients, it is important that we understand the areas of our business that are working and the areas that need improvement.

Overall, 100% of clients who responded to our survey gave Alliance Pharma a rating of SATISFIED or higher in regards to questions about services, personnel, performance, support, management, and costs. In fact, 75% of clients stated that they are VERY SATISFIED with Alliance Pharma.

The Customer Survey went out to Scientific Directors, Senior Research Directors, Assistant Scientists, Senior Managers, and Professors. When these clients were asked, “How satisfied are you with the performance of our technicians?” 70% replied that they are VERY SATISFIED. In addition, 65% of our clients responded that they are VERY SATISFIED with our management’s commitment to assist.

Customer Survey Data

We also used the survey to understand why our clients are choosing to partner with us. We know that there are many CROs in the marketplace, so we value each and every client. The replies showed that our network is strong and that referrals are the number one factor for our clients choosing to partner with us. The survey also revealed that our clients are choosing us for other reasons, as follows:

• Timing
• Cost
• Quality
• Location
• Assay Capability

Customer Focused Improvements

Based on the results of the survey, we plan to update our website design and functionality. We will also create new company literature to describe the full extent of our services, especially those that we have added this year, such as the Laboratory Animal Facility and Large Molecule Bioanalysis.

Alliance Pharma would like to thank all of our customers for their time in completing the survey to help us understand how we can better serve all your needs! We are committed to delivering the highest quality services at a competitive price, and thus build a lasting partnership. Thank you for your continued patronage.

On November 13, our team of top scientists traveled to Denver, Colorado for the 2016 AAPS Annual Conference for pharmaceutical scientists. The conference was kicked off with a keynote address from Daniel Fletcher, PhD who discussed novel technology, new delivery modalities, accelerated drug development, and precision medicine. Our booth, which was serendipitously situated next to the Rest and Relaxation Lounge, welcomed a host of pharmaceutical professionals, academic leaders, and job-seekers. Visitors received an Alliance Pharma lunchbox or a handy letter opener.

Many connections were made at the various networking events like the Welcome-Reception, the American Chinese Pharmaceutical Association Meeting, and the 80’s Party hosted by Core RX and Mutchler Inc. Presenters and attendees at the conference included Teva, BASF, Agilent, Triangle Research Labs, Science Exchange, MedPace, and Pfizer, to name a few. Many members of the FDA were also onsite.

Researchers seeking a CRO (contract research organization) find value in the conference because they can make a trusted in-person connection and quickly discern the qualities of a specific CRO. For example, the ideal CRO offers quick-turn around, high-quality data, and competitive pricing. The conference was also an opportunity to share updates on our company. This year, Alliance Pharma had added a Vivarium for animal research studies and a new lab for Large Molecule Bioanalysis.

Tweets from #AAPS2016

Dr. Meng Feng presented a poster on microsampling titled Mouse Pharmacokinetic Study of Ceftriaxone Using Mitra^TM Microsampling Devices. (View the full details here.) In his work with a group of Alliance colleagues, Dr. Feng concluded that Mitra^TM microsampling devices provide a methodology that can be used for serial blood sampling in drug discovery mouse studies, and which could reduce costs, improve animal welfare, and save precious test articles.

Dr. Yong Lin presented a poster on Adaptation and Validation of a Multiplex Assay Kit for the Quantitative Analysis of Aβ38, Aβ40, and Aβ42 Peptides in Cynomolgus Monkey Plasma at AAPS. (View the original poster here.)

2017 Conference for Pharmaceutical Scientists

If you are seeking another conference for pharmaceutical scientists, consider joining us in 2017 at one of our upcoming events. View the full conference schedule here.

On Sunday, May 3, 2015, Alliance Pharma participated along with 40,000 people in Boston’s 47th annual “Walk for Hunger.” The 20-mile route wound around Boston and surrounding communities and raised money to create sustainable solutions for hunger in Massachusetts. This year’s walk raised more than $3 million. Alliance Pharma raised $500 and walked the whole 20 miles to support this great cause. Thank you for your donations and support!

In 2014, Alliance Pharma was recognized as one of the 100 fastest growing private companies in Philadelphia by the Philadelphia Business Journal. 

Alliance Pharma has successfully completed testing and validation of the Meso Scale Discovery® (MSD) Human V-PLEX Aβ Peptide Panel 1 Assay (6E10).  With the completion of this validation, Alliance Pharma becomes the first global CRO to validate the Aβ V-PLEX Panel 1, and greatly expands its analytical capabilities in Alzheimer’s and Neurodegenerative Diseases.

The MSD Aβ V-PLEX Panel 1 (6E10) is a multiplexed sandwich immunoassay which measures three amyloid peptides of significance to Alzheimer’s disease: Aβ42, Aβ40, and Aβ38.  MSD neurodegenerative disease assays provide a sensitive method for measuring the levels of peptide and protein targets within a single, small-volume sample.  V-PLEX immunoassays are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles.

Sensitive biomarker assays are proving crucial to the design and execution of clinical trials that target the earliest stages of Alzheimer’s disease.  The Aβ Peptide Panel 1 (6E10) kit is validated for human CSF and thus is ideally suited for this purpose.

“The addition of the Meso Scale Discovery® MSD Aβ V-PLEX immunoassay to our service portfolio will further help our sponsors in the development of drugs to treat neurodegenerative diseases” said Dr. Feng Li, President of Alliance Pharma.

FENG LI
CEO
ALLIANCE PHARMACEUTICALS
MALVERN

Years in business: 6

What made you start your business?
I got the idea a long time ago. I worked in same industry as I am now. I got intensive training. I appreciate the experience I got from that company. I was working very hard at learning and thinking about starting the business. By 2006, I began doing research on how to prepare for new business.

What did you do to survive the recession?
Alliance Pharmaceuticals was started in May 2008. We spent almost $1 million, however, only made about $28,000 with three key employees that year. We stuck with our initial business plan, focused on our expertise area, spent time to build up necessary functionalities and prepare for any potential business opportunities. All three employees deferred their pay for a year to ensure the business operation.

What has made your business successful?
We firmly adhere with our business philosophy including professional ethics, scientific excellence, regulatory compliance to win clients trust. We also have maximum business flexibility to understand our clients needs to meet and exceed their expectations.

What is the hardest part of your job?
The regulatory compliance to ensure the data quality and integrity and hiring the right employees.

What advice would you give someone starting their career or looking to start a business?
Have a dream, make a plan, prepare and execute it. You also must be confident enough to be persistent.

Would your advice be any different if you were addressing a minority?
There is no difference. The principle would be the same.

Excerpt from Philadelphia Business Journal